相似文献
1
The CANTOS Trial: One Important Step for Clinical Cardiology but a Giant Leap for Vascular Biology.
Arterioscler Thromb Vasc Biol. 2017 Nov;37(11):e174-e177. doi: 10.1161/ATVBAHA.117.310097. Epub 2017 Sep 28.
2
Inflammation and Atherosclerosis: The End of a Controversy.
Circulation. 2017 Nov 14;136(20):1875-1877. doi: 10.1161/CIRCULATIONAHA.117.030484. Epub 2017 Sep 15.
3
From clinical observations to molecular mechanisms and back to patients: the successful circuit of the CANTOS study.
Cardiovasc Res. 2018 Jan 1;114(1):e3-e5. doi: 10.1093/cvr/cvx219.
4
Inflammation and atherosclerosis: fulfilling Koch's postulates.
Ther Adv Cardiovasc Dis. 2018 Jan;12(1):5-6. doi: 10.1177/1753944717744740. Epub 2017 Nov 30.
5
Inflammation and coronary artery disease: from pathophysiology to Canakinumab Anti-Inflammatory Thrombosis Outcomes Study (CANTOS).
Coron Artery Dis. 2018 Aug;29(5):429-437. doi: 10.1097/MCA.0000000000000625.
6
Inflammation and cardiovascular diseases: lessons from seminal clinical trials.
Cardiovasc Res. 2021 Jan 21;117(2):411-422. doi: 10.1093/cvr/cvaa211.
7
Mortality Differences Associated With Treatment Responses in CANTOS and FOURIER: Insights and Implications.
Circulation. 2018 Apr 24;137(17):1763-1766. doi: 10.1161/CIRCULATIONAHA.117.033254. Epub 2017 Dec 22.
8
Role of vascular inflammation in coronary artery disease: potential of anti-inflammatory drugs in the prevention of atherothrombosis. Inflammation and anti-inflammatory drugs in coronary artery disease.
Am J Cardiovasc Drugs. 2015 Feb;15(1):1-11. doi: 10.1007/s40256-014-0094-z.
9
CANTOS - is selective targeting of inflammation in atherosclerosis enough?
J R Coll Physicians Edinb. 2018 Sep;48(3):246-247. doi: 10.4997/JRCPE.2018.310.
10
From RESCUE to ZEUS: will interleukin-6 inhibition with ziltivekimab prove effective for cardiovascular event reduction?
Cardiovasc Res. 2021 Sep 28;117(11):e138-e140. doi: 10.1093/cvr/cvab231.
引用本文的文献
1
Attenuation of adipose tissue inflammation by pro-resolving lipid mediators.
Curr Opin Endocr Metab Res. 2024 Sep;36:100539. doi: 10.1016/j.coemr.2024.100539.
2
Nanomedicines for cardiovascular disease.
Nat Cardiovasc Res. 2023 Apr;2(4):351-367. doi: 10.1038/s44161-023-00232-y. Epub 2023 Apr 3.
3
Novel Long Noncoding RNA Affects Monocyte Subtypes, Reducing Inflammation and Promoting Vascular Healing.
Circulation. 2024 Oct;150(14):1101-1120. doi: 10.1161/CIRCULATIONAHA.124.069315. Epub 2024 Jul 15.
4
Novel Mouse Model of Myocardial Infarction, Plaque Rupture, and Stroke Shows Improved Survival With Myeloperoxidase Inhibition.
Circulation. 2024 Aug 27;150(9):687-705. doi: 10.1161/CIRCULATIONAHA.123.067931. Epub 2024 Jun 17.
5
The association between lipid levels and leukocyte count: A cross-sectional and longitudinal analysis of three large cohorts.
Am Heart J Plus. 2021 Jun 24;4:100024. doi: 10.1016/j.ahjo.2021.100024. eCollection 2021 Apr.
6
Biomimetic nanodrug targets inflammation and suppresses YAP/TAZ to ameliorate atherosclerosis.
Biomaterials. 2024 Apr;306:122505. doi: 10.1016/j.biomaterials.2024.122505. Epub 2024 Feb 7.
7
Macrophage immunometabolism in diabetes-associated atherosclerosis.
Immunometabolism (Cobham). 2023 Oct 16;5(4):e00032. doi: 10.1097/IN9.0000000000000032. eCollection 2023 Oct.
8
Therapeutic targeting of chronic kidney disease-associated DAMPs differentially contributing to vascular pathology.
Front Immunol. 2023 Oct 2;14:1240679. doi: 10.3389/fimmu.2023.1240679. eCollection 2023.
9
Targeted imaging: the key for direct visualization of myocardial inflammation in patients?
J Nucl Cardiol. 2023 Dec;30(6):2556-2558. doi: 10.1007/s12350-023-03370-9. Epub 2023 Sep 20.
10
Novel Anti-Inflammatory Therapies in Coronary Artery Disease and Acute Coronary Syndromes.
Life (Basel). 2023 Jul 31;13(8):1669. doi: 10.3390/life13081669.
本文引用的文献
1
Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial.
Lancet. 2017 Oct 21;390(10105):1833-1842. doi: 10.1016/S0140-6736(17)32247-X. Epub 2017 Aug 27.
2
Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease.
N Engl J Med. 2017 Sep 21;377(12):1119-1131. doi: 10.1056/NEJMoa1707914. Epub 2017 Aug 27.
3
Targeting Inflammation in Coronary Artery Disease.
N Engl J Med. 2017 Sep 21;377(12):1197-1198. doi: 10.1056/NEJMe1709904. Epub 2017 Aug 27.
4
Flow Perturbation Mediates Neutrophil Recruitment and Potentiates Endothelial Injury via TLR2 in Mice: Implications for Superficial Erosion.
Circ Res. 2017 Jun 23;121(1):31-42. doi: 10.1161/CIRCRESAHA.117.310694. Epub 2017 Apr 20.
5
How Common Is Residual Inflammatory Risk?
Circ Res. 2017 Feb 17;120(4):617-619. doi: 10.1161/CIRCRESAHA.116.310527.
6
Clonal hematopoiesis associated with TET2 deficiency accelerates atherosclerosis development in mice.
Science. 2017 Feb 24;355(6327):842-847. doi: 10.1126/science.aag1381. Epub 2017 Jan 19.
7
Temporal shifts in clinical presentation and underlying mechanisms of atherosclerotic disease.
Nat Rev Cardiol. 2017 Jan;14(1):21-29. doi: 10.1038/nrcardio.2016.166. Epub 2016 Oct 20.
8
Arterial Effects of Canakinumab in Patients With Atherosclerosis and Type 2 Diabetes or Glucose Intolerance.
J Am Coll Cardiol. 2016 Oct 18;68(16):1769-1780. doi: 10.1016/j.jacc.2016.07.768.
9
Activation of the pluripotency factor OCT4 in smooth muscle cells is atheroprotective.
Nat Med. 2016 Jun;22(6):657-65. doi: 10.1038/nm.4109. Epub 2016 May 16.
10
Acute coronary syndromes without coronary plaque rupture.
Nat Rev Cardiol. 2016 May;13(5):257-65. doi: 10.1038/nrcardio.2016.19. Epub 2016 Feb 25.
Zotero 插件